8-K: Harvard Bioscience Reports Q4, Full-Year 2025 Results

Harvard Bioscience announced its fourth quarter and full-year 2025 financial results, alongside 2026 guidance and the permanent appointment of Mark Frost as CFO.

Summary

• Fourth quarter 2025 revenues were $23.7 million, a decrease from $24.6 million in Q4 2024.
• Fourth quarter 2025 gross margin improved to 59.7% from 57.1% in Q4 2024.
• Fourth quarter 2025 net loss was ($2.8) million, compared to net income of $18 thousand in Q4 2024.
• Fourth quarter 2025 Adjusted EBITDA increased to $3.8 million from $3.0 million in Q4 2024.
• Full year 2025 revenues were $86.6 million, down from $94.1 million in full year 2024.
• Full year 2025 gross margin was 57.7%, a slight decrease from 58.2% in full year 2024.
• Full year 2025 net loss significantly widened to ($56.7) million from ($12.4) million in 2024, primarily due to a $48.0 million goodwill impairment in Q1 2025.
• Full year 2025 Adjusted EBITDA increased to $8.1 million from $7.2 million in full year 2024.
• Cash provided by operations for full year 2025 was $6.7 million, a substantial increase from $1.4 million in 2024.
• Mark Frost has been appointed Chief Financial Officer on a permanent basis.
• The company introduced full year 2026 guidance, projecting revenue growth between 2% and 4%, adjusted gross margin between 58% and 60%, and Adjusted EBITDA growth between 6% and 10%.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed but forward-looking report. While 2025 GAAP results were significantly impacted by non-cash charges and revenue decline, underlying operational metrics (Adjusted EBITDA, cash flow) showed improvement, and the 2026 guidance projects growth, signaling a potential turnaround.

Positives

• Q4 2025 gross margin increased to 59.7% from 57.1% in Q4 2024, driven by cost containment actions and a favorable product mix.
• Q4 2025 Adjusted EBITDA increased to $3.8 million from $3.0 million in Q4 2024.
• Full Year 2025 Adjusted EBITDA increased to $8.1 million from $7.2 million in Full Year 2024.
• Full Year 2025 cash provided by operations significantly increased to $6.7 million from $1.4 million in Full Year 2024, reflecting a strengthened balance sheet and streamlined operating model.
• The company is strategically evolving into a leading enabler of translational science, focusing on new products for higher-margin New Product Innovation (NPI) revenue.
• Full Year 2026 guidance projects revenue growth of 2-4% and Adjusted EBITDA growth of 6-10%, indicating anticipated operational improvement.
• Expectations for 2026 include a stabilized NIH funding environment and a reduction in tariff disruptions.
• Mark Frost's permanent appointment as CFO provides leadership stability and continuity.

Negatives

• Q4 2025 revenues declined to $23.7 million from $24.6 million in Q4 2024.
• Q4 2025 net loss was ($2.8) million, a significant decline from net income of $18 thousand in Q4 2024.
• Full Year 2025 revenues declined to $86.6 million from $94.1 million in Full Year 2024, attributed to a challenging global market and reduced spending by CROs, distributors, and academic research institutions.
• Full Year 2025 gross margin slightly decreased to 57.7% from 58.2% in 2024, unfavorably impacted by the under-absorption of fixed manufacturing overhead costs.
• Full Year 2025 net loss significantly widened to ($56.7) million from ($12.4) million in 2024, primarily due to a $48.0 million goodwill impairment in the first quarter of 2025.
• Full Year 2025 net loss included ($1.8) million in debt refinancing costs and a ($1.2) million loss on pension settlement.
• Cash used in operations for Q4 2025 was ($0.1) million, compared to $1.7 million provided in the same period of 2024.
• First Quarter 2026 revenue guidance of $20.0 million to $22.0 million and Adjusted EBITDA guidance of $1.0 million to $2.2 million are lower than Q4 2025 actuals.

Risks

• Challenging global market conditions impacting revenue.
• Reduced spending by Contract Research Organizations (CROs), distributors, and academic research institutions.
• Under-absorption of fixed manufacturing overhead costs unfavorably impacting gross margin.
• Risk of significant non-cash charges such as goodwill impairment (a $48.0 million charge occurred in Q1 2025).
• Costs associated with debt refinancing activities.
• Losses related to pension settlements.
• Ongoing impact of tariffs on financial results.
• Headwinds from NIH funding, although expected to stabilize in 2026.
• General uncertainties, risks, assumptions, and contingencies inherent in forward-looking statements, many of which are outside the Company’s control.

Future Outlook

The Company anticipates a new phase of growth in 2026 and beyond, driven by a strategic evolution from a traditional life science tools provider to a leading enabler of translational science. This involves focusing on new products for translational science and embracing New Approach Methodologies (NAMs) to help customers generate more predictive, human-relevant data earlier in drug development. Full Year 2026 guidance projects revenue growth of 2-4%, adjusted gross margin of 58-60%, and Adjusted EBITDA growth of 6-10%, supported by a stabilized NIH funding environment and reduced tariff disruptions.

Management Comments

• John Duke, President and CEO: "2025 was a pivotal year for Harvard Bioscience as we strengthened our balance sheet and streamlined our operating model. This culminated in fourth quarter results that reflect disciplined execution, an improved product mix, and the cost reductions implemented throughout the year."
• John Duke, President and CEO: "As we look ahead, we are evolving from a traditional life science tools provider into a leading enabler of translational science. By embracing the ongoing shift to New Approach Methodologies (NAMs) and focusing on new products for translational science, we'll help our customers generate more predictive, human-relevant data earlier in the drug development process."
• John Duke, President and CEO: "We believe we are well-positioned for a new phase of growth and are confident in our outlook and our ability to drive sustainable shareholder value in 2026 and beyond."
• Mark Frost, CFO: "I'm pleased to have been appointed on a permanent basis and to continue working with the Harvard Bioscience team. We've made significant progress over the past year. I'm excited by the opportunity ahead, and I look forward to further engagement with our team, customers, and shareholders."

Industry Context

StockSavvy.ai notes that Harvard Bioscience's strategic shift towards "translational science" and "New Approach Methodologies (NAMs)" aligns with a broader industry trend in life sciences to accelerate drug development through more predictive, human-relevant data. The mention of a "stabilized NIH funding environment" and "reduced spending by CROs, distributors and academic research institutions" highlights the sensitivity of the life science tools sector to government funding and research budgets, which have been volatile. The company's focus on higher-margin New Product Innovation (NPI) is a common strategy for companies in mature or challenging markets to improve profitability and differentiate themselves.

Comparison to Industry Standards

• This filing does not provide specific comparable companies, projects, or results to assess against global benchmarks. Therefore, a direct comparison to industry standards is not possible based solely on the provided text.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased shareholder value through anticipated revenue and Adjusted EBITDA growth, and strategic pivot. However, significant GAAP net losses in 2025 could be a concern.
• Employees: Cost containment actions and headcount reductions mentioned in 2024 and 2025 indicate potential impacts on the workforce.
• Customers: The strategic focus on new products for translational science and New Approach Methodologies (NAMs) aims to provide more predictive, human-relevant data, potentially benefiting customers in drug development.
• Creditors: Debt refinancing activities and improved cash flow from operations could positively impact the company's ability to service its debt.

Next Steps

• A conference call and webcast will be held on March 12, 2026, at 8:00 AM ET to discuss the results.
• A presentation referenced during the webcast will be posted to the Company's Investor Relations website.
• The company will continue its strategic focus on evolving into a leading enabler of translational science, embracing New Approach Methodologies (NAMs), and introducing new products.
• Driving sustainable shareholder value in 2026 and beyond is a key objective.

Key Dates

Recommendation

While the company reported a substantial GAAP net loss for 2025 primarily due to a non-cash goodwill impairment, the underlying operational metrics (Adjusted EBITDA, cash from operations) showed improvement. The strategic pivot towards translational science and positive 2026 guidance for revenue and Adjusted EBITDA growth suggest a potential turnaround. However, the revenue decline in 2025 and the lower Q1 2026 guidance indicate ongoing challenges. A "Hold" recommendation reflects a wait-and-see approach to observe if the strategic initiatives and projected growth materialize consistently.

Keywords

Harvard Bioscience, HBIO, financial results, Q4 2025, full year 2025, 2026 guidance, revenue, gross margin, Adjusted EBITDA, net loss, cash flow, translational science, New Approach Methodologies, NAMs, life science tools, CFO appointment, earnings